Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Amycretin, an oral weight loss pill developed by the makers of Wegovy, led to a 13.1% weight loss over three months in early ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

A daily diet pill has shown promising results in early trials, with participants losing an average of 13% of their body ...

Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

Amycretin mimics the actions of glucagon-like peptide-1 (GLP-1) and amylin, hormones that play a role in reducing blood sugar ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

If you guessed weight loss, you are right on the money. Therapies in this field, such as Eli Lilly's Zepbound and Novo Nordisk's Wegovy, are generating mouthwatering sales, so it's no wonder other ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...